EHA: European Hematology Association

Conference Coverage

Drug proves active in resistant MM

STOCKHOLM—The alkylating peptide melflufen has demonstrated activity in patients with treatment-resistant multiple myeloma (MM). In a phase 2...

Conference Coverage

‘Very encouraging’ results in BPDCN

STOCKHOLM—Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell...

Conference Coverage

Voxelotor benefits adolescents with SCD

STOCKHOLM—An ongoing phase 2 study suggests voxelotor (GBT440) can benefit adolescents with sickle cell disease (SCD). In the HOPE-KIDS 1 study,...

Conference Coverage

Survey reveals patient perceptions of ITP

STOCKHOLM—A new survey has revealed patients’ perceptions of immune thrombocytopenia (ITP) and how the condition impacts their quality of life (...

Conference Coverage

Inhibitor elicits responses in cGVHD

STOCKHOLM—The ROCK2 inhibitor KD025 produced responses in about two-thirds of patients with steroid-dependent or refractory chronic graft-versus-...

Conference Coverage

MAb doubles ORR, PFS in rel/ref MM

STOCKHOLM—Adding elotuzumab (E) to treatment with pomalidomide (P) and low-dose dexamethasone (d) can produce “clinically meaningful” results in...

Pages